Extensive exposure to solar ultraviolet radiation (UVR) is a well-recognized etiologic factor for cutaneous non-melanoma skin cancer. In this issue of the Journal, Singh et al. show that topical treatment of skin with 17-[allylamino]-17-demethoxygeldanamycin (17AAG), a heat-shock protein 90 (Hsp90) inhibitor, prevents UVR-induced squamous cell carcinomas (SCC) in mice. The inhibitory effect of 17AAG on SCC was associated with the inhibition of the UVR-induced: (i) hyperplastic response, (ii) Hsp90β-PKCε interaction, and (iii) pStat3 and pAkt expression in mouse skin.
Multiple molecular targets, including inflammatory mediators, oxidative stress, DNA damage and repair, and immunological responses, have been identified that are responsible for the prevention of UVR-induced skin carcinogenesis by these phytochemicals.
The research laboratory of Dr. Verma and colleagues reported the activation of PKCε, a novel PKC isoform, in UVR-exposed skin and demonstrated that PKCε activation mediates UVR-induced TNFα release, which is linked to the development of SCCs (Wheeler et al., 2004) . PKCε is among the six PKC isoforms (α, δ, ε, μ, ξ, η) that are expressed in both human and mouse skin. PKCε overexpression has been shown to decrease the latency, while increasing the incidence and multiplicity of the SCCs in PKCε transgenic mice (Wheelar et al., 2004) . It has been reported that the possible mechanisms by which PKCε mediates susceptibility to SCC induction include PKCε-mediated anti-apoptotic and cell survival signals (Aziz et al., 2007) . The PKCε-mediated cell survival signal may involve interaction of PKCε with Stat3, which also has been linked to the induction of skin cancer (Goetz et al., 2005) .
In this issue of the Journal, Singh and colleagues (2014) have shown that UVR exposure increases the interaction of PKCε with heat-shock protein 90β (Hsp90β) and that this interaction may play an important role in UVR-induced SCCs. The chaperone Hsp90 mediates the maturation and stabilization of PKCε as a client protein (Gould et al., 2009) , and it also plays a significant role in cell transformation, proliferation and cell survival (Miyata et al., 2013) . Hsp90 is of considerable interest as an oncogenic target since tumor cells and oncogenic proteins are heavily dependent on its activity (Soti et al., 2005) . By inhibiting Hsp90 one can target a large number of downstream proteins and thereby attack the neoplastic process at several points as illustrated in Figure 1 . Consequently, several Hsp90 inhibitors have been developed and are being evaluated for treatment of various human cancers (Cullinan and Whitesell, 2006) . Geldanamycin, the first Hsp90 inhibitor to be tested in a clinical trial, failed due to hepatotoxicity. Second-generation derivatives, such as 17-[allylamino]-17-demethoxygeldanamycin (17AAG), do not cause liver toxicity and currently are being evaluated in phase II clinical trials (Heath et al., 2008; Pacey et al., 2012) . A large number of clinical trials are exploring the use of 17AAG and other Hsp90 inhibitors in various cancers including melanoma (Cullinan and Whitesell, 2006) ; however, Hsp90 inhibitors have never been investigated in terms of the prevention and treatment of UVR-induced SCC. As many of the molecular targets in UVR-induced skin carcinogenesis are dependent on Hsp90 for maturity, stability and activity, Singh and colleagues formulated the hypothesis that treatment of Hsp90 inhibitor in conjunction with UVR exposure will prevent development of cutaneous SCCs. They demonstrate that topical treatment with the Hsp90 inhibitor, 17AAG, was not toxic and that it was effective in preventing UVR-induced SCC development in mice in terms of: 1) inhibition of tumor incidence and tumor multiplicity and 2) increased latency for first tumor appearance. These results concerning tumor development were verified in three mouse models: SKH-1 hairless, wild-type FVB, and PKCε overexpressing transgenic FVB mice. in increased expression of PKCε, possibly due to its increased synthesis. They also demonstrate that topical application of 17AAG to mouse skin inhibits UVR-induced Hsp90β-PKCε interaction as well as expression levels of pStat3 and pAkt. These findings are consistent with the requirement for sequential phosphorylation of newly synthesized PKC and its binding to Hsp90, which is a required step in its maturation and stability (Gould et al., 2009) .
In this issue of the Journal, Singh and colleagues also report the effects of 17AAG on the biomarkers of chronic UVR-induced photoaging of the skin. Overexpression of matrix metalloproteinases (MMP) in UV-exposed skin has been implicated in the wrinkling of skin or premature aging that is known as photoaging. Topical treatment of SKH-1 hairless mouse skin with 17AAG before and after UVR exposure resulted in decreased levels of MMP-2 and MMP-9 proteins as compared with mouse skin that was not treated with 17AAG but exposed to UVR. These results suggest that 17AAG treatment may protect the skin from photoaging through inhibition of MMPs.
Singh and colleagues have demonstrated convincingly that 17AAG has the ability to inhibit UVR-induced SCCs development and also to inhibit selected biomarkers of photoaging. However, UVR-induced development of SCCs accompanies expression and activation of several oncogenic signal transduction pathways, as summarized in Figure 1 . Thus, more rigorous, mechanism-based studies are warranted to establish the molecular mechanisms underlying prevention of UVR-induced SCCs in the skin by 17AAG. Further studies may reveal broader mechanisms of action of the Hsp90 inhibitor, 17AAG. Skin exposure to UVR induces the activation of multiple signal transduction pathways culminating in activation of transcription factors (AP1, NF-κB, Stat3, etc.) and constitutive expression of genes (e.g., cytokines, COX-2, cyclin D1, Survivin, etc.), essential for SCC development. The molecular targets in UVR-induced skin carcinogenesis require Hsp90 for their maturity, stability and activity. 17AAG inhibits UVR-induced SCC via inhibition of Hsp90 ATPase activity essential for the stability of UVR-activated signal transduction pathways.
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